Brenda Libby Coleman

Array ( [id] => 20651450 [patent_doc_number] => 20260103463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-16 [patent_title] => PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT [patent_app_type] => utility [patent_app_number] => 19/247822 [patent_app_country] => US [patent_app_date] => 2025-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19247822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20722269 [patent_doc_number] => 20260138972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-21 [patent_title] => PREPARATION METHOD AND CHIRAL SIEVING APPLICATION OF NOVEL 12-CROWN-4 COVALENT ORGANIC FRAMEWORKS [patent_app_type] => utility [patent_app_number] => 19/019867 [patent_app_country] => US [patent_app_date] => 2025-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19019867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961566 [patent_doc_number] => 12331050 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Pyrazolopyridine derivative having GLP-1 receptor agonist effect [patent_app_type] => utility [patent_app_number] => 18/820993 [patent_app_country] => US [patent_app_date] => 2024-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 31752 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18820993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321299 [patent_doc_number] => 20250333387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALT [patent_app_type] => utility [patent_app_number] => 18/806836 [patent_app_country] => US [patent_app_date] => 2024-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18806836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19497564 [patent_doc_number] => 20240336582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/745710 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846712 [patent_doc_number] => 20250092063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => Substituted Macrocyclic Compounds and Related Methods of Treatment [patent_app_type] => utility [patent_app_number] => 18/745031 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745031 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556421 [patent_doc_number] => 20240368213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS [patent_app_type] => utility [patent_app_number] => 18/741425 [patent_app_country] => US [patent_app_date] => 2024-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20419415 [patent_doc_number] => 20250381500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-18 [patent_title] => SOLVATE AND METHOD OF MANUFACTURING SOLVATE [patent_app_type] => utility [patent_app_number] => 18/741024 [patent_app_country] => US [patent_app_date] => 2024-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18741024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20362694 [patent_doc_number] => 20250352506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-20 [patent_title] => MRGPRB2/X2, AGONIST AND ANTAGONIST AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 18/667291 [patent_app_country] => US [patent_app_date] => 2024-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13815 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18667291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20824901 [patent_doc_number] => 12678443 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-14 [patent_title] => Medicament for preventing and/or treating dry eye [patent_app_type] => utility [patent_app_number] => 18/655985 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 1132 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19504942 [patent_doc_number] => 12116353 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-10-15 [patent_title] => Crystalline chloro-n-(4-(morpholinomethyl)phenyl)benzamide and crystalline hydrochloride salt [patent_app_type] => utility [patent_app_number] => 18/645972 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 11819 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601053 [patent_doc_number] => 20240391933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE [patent_app_type] => utility [patent_app_number] => 18/646220 [patent_app_country] => US [patent_app_date] => 2024-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18646220 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556390 [patent_doc_number] => 20240368182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => Substituted Macrocyclic Compounds and Related Methods of Treatment [patent_app_type] => utility [patent_app_number] => 18/628635 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43621 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18628635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667416 [patent_doc_number] => 12180143 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-31 [patent_title] => 8-((4-hydroxy-3-methoxyphenyl)diazenyl)naphthalene-1,3-disulfonic acid as an antioxidant compound [patent_app_type] => utility [patent_app_number] => 18/611685 [patent_app_country] => US [patent_app_date] => 2024-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3878 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19614821 [patent_doc_number] => 20240400501 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => 3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/601679 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18601679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846711 [patent_doc_number] => 20250092062 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/592020 [patent_app_country] => US [patent_app_date] => 2024-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 1249 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18592020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20593523 [patent_doc_number] => 12577225 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-17 [patent_title] => Nuclear transport modulators and uses thereof [patent_app_type] => utility [patent_app_number] => 18/586019 [patent_app_country] => US [patent_app_date] => 2024-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 28206 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18586019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332541 [patent_doc_number] => 20240246971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT [patent_app_type] => utility [patent_app_number] => 18/584672 [patent_app_country] => US [patent_app_date] => 2024-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35350 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20213526 [patent_doc_number] => 12410168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-09 [patent_title] => Pyrazolopyridine derivative having GLP-1 receptor agonist effect [patent_app_type] => utility [patent_app_number] => 18/584177 [patent_app_country] => US [patent_app_date] => 2024-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 31403 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20701332 [patent_doc_number] => 12624032 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases [patent_app_type] => utility [patent_app_number] => 18/581677 [patent_app_country] => US [patent_app_date] => 2024-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 24 [patent_no_of_words] => 9040 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18581677 [rel_patent_id] =>[rel_patent_doc_number] =>)